Pfizer (NYSE:PFE) Announces Quarterly Earnings Results

Pfizer (NYSE:PFE) posted its earnings results on Tuesday. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13, Zacks reports. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the company earned $0.87 earnings per share. The business’s quarterly revenue was down .4% on a year-over-year basis.

Here are the key takeaways from Pfizer’s conference call:

• Pfizer raised its 2026 guidance, increasing revenue expectations to $62 billion–$64 billion and adjusted diluted EPS to $2.95–$3.05, supported by strong year-to-date execution.
• Non-COVID products grew 7% operationally, while launched and acquired products increased 32%, led by PADCEV, NURTEC, and LORBRENA. Pfizer said it remains on track to deliver nearly all of its planned $7.2 billion in net savings by the end of 2026 and expects an additional $2.5 billion in savings from 2027–2029.
• Management highlighted encouraging pipeline progress, including positive phase III data for ELREXFIO, promising results for atirmociclib and tivunatamig, and continued development of obesity treatments berobenatide and amylin combinations. Pfizer expects multiple regulatory decisions, readouts, and pivotal study starts over the next 12 months.
• Pfizer continues to face a significant loss-of-exclusivity transition, including upcoming pressure from IBRANCE and XTANDI in the U.S. and ELIQUIS internationally. COVID-19 products and the PREVNAR family declined in the quarter, while 2027 results will also reflect IRA, 340B, MFN, and pricing impacts.

Pfizer Stock Performance

PFE stock traded down $0.42 during mid-day trading on Thursday, hitting $30.36. The company had a trading volume of 25,449,561 shares, compared to its average volume of 39,762,148. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market cap of $173.07 billion, a PE ratio of 43.44, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. Pfizer has a 12 month low of $23.62 and a 12 month high of $31.44. The stock’s fifty day moving average price is $28.69 and its two-hundred day moving average price is $26.86.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.7%. Pfizer’s payout ratio is currently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Guggenheim raised its price target to $33 from $31 and assigned a Buy rating, signaling potential upside. Guggenheim rating update
• Positive Sentiment: Pfizer’s latest quarterly report showed momentum in newer and acquired medicines, with those products growing 32% operationally. The company also raised its 2026 revenue and adjusted-earnings outlook, providing a fundamental support for the shares. Pfizer: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Pfizer reported an update to its Phase 3 study of a monthly obesity drug, an area that could offer a competitive growth opportunity. The available report does not provide trial results, so the update’s investment significance is unclear. Pfizer Advances Monthly Obesity Drug Study
• Negative Sentiment: Goldman Sachs maintained a Hold rating, tempering the bullish analyst call. The cautious stance may weigh on sentiment as investors assess whether recent earnings strength and pipeline prospects can sustain Pfizer’s rally. Goldman Sachs Remains a Hold on Pfizer

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. UBS Group boosted their price target on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. Guggenheim raised their price objective on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday. Argus set a $40.00 target price on shares of Pfizer in a research report on Wednesday. Cantor Fitzgerald boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a report on Wednesday. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $29.94.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.